GlassScriptPhysician profile
Allison Hinko
NPI 1255612941
$3,435.50
in general payments reported to CMS, 2019-2025
20 companies · $81.12 in 2025
The $81.12 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $229 · 2021: $503 · 2022: $569 · 2023: $521 · 2024: $991 · 2025: $81.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $476.28 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $458.62 | 2023-2025 | Syfovre |
| Genentech USA, INC. | $440.69 | 2019-2024 | Vabysmo |
| Sight Sciences, INC. | $339.26 | 2019-2024 | Omni Surgical System |
| Rxsight INC | $266.65 | 2021-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Alcon Vision LLC | $247.98 | 2020-2024 | Clareon |
| Microsurgical Technology, INC. | $241.68 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $225.58 | 2021-2022 | |
| Biotissue Holdings INC. | $222.50 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $135.13 | 2019-2020 | |
| Biogen, INC. | $116.13 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.83 | 2019-2021 | |
| Allergan, INC. | $51.58 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $37.95 | 2024 | Envista Mx60 Iol |
| Novartis Pharmaceuticals Corporation | $29.55 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.89 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $18.15 | 2024 | Xdemvy |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Aerie Pharmaceuticals, INC. | $16.10 | 2021 | |
| Kala Pharmaceuticals, INC. | $15.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hinko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.